Merck, Caprotec Collaborate on Protein-Drug Interaction Research
Caprotec Bioanalytics said this week it and Merck KGaA reached an agreement for use of Caprotec’s Capture Compound Mass Spectrometry technology for the identification of relevant protein-drug molecule interactions. Merck KGaA was acting on behalf of its Merck Serono division in reaching the agreement with Caprotec.
The technology will be applied to an undisclosed Merck Serono research project.
Caprotec will receive research funding and potential milestone payments on product development. No other financial details were disclosed.
Caprotec, based in Berlin, was formed late last year. Its CCMS platform is based on tri-functional molecules called capture compounds that allow for the isolation of proteins and protein classes directly from complex biological samples.
GeneBio, Protagen to Co-Distribute of PTM-Detection Software
GeneBio will distribute worldwide Protagen’s Modiro detection software for post-translation modifications under a global agreement announced this week.
In addition, the two companies will collaborate to link Modiro functionalities to GeneBio’s Phenyx software platform for mass spec data analysis. Financial terms of the deal were not disclosed.
Modiro allows for better and more thorough detection of post-translational modifications, the company said in a statement, while its automated mode cuts down on time and workload.
New Name for National Stem Cell Holding: Proteomix
National Stem Cell Holding said this week it will change its name to Proteomix to reflect the company’s maturation from an R&D firm to a technology-commercialization outfit.
These technologies “relate in great part” to the identification of proteins and their structure and functions within the biotherapeutics field, the company said in a statement. The company said it also intends to begin marketing it portfolio of biomarkers to research laboratories globally.
Based in Mountainside, NJ, National Stem Cell focuses on developing therapeutics based on human cells and their derivatives. It develops proprietary stem cell therapeutics focusing on diabetes and cardiac diseases.
PerkinElmer Declares Dividend
PerkinElmer’s board this week declared a regular quarterly dividend of $.07 per share. The dividend is payable on Aug. 8 to shareholders of record as of the close of business day July 18.